RESUMEN
Many cull dairy cows enter the marketing system and travel to widely dispersed and specialized slaughter plants, and they may experience multiple handling events (e.g., loading, unloading, mixing), change of ownership among dealers, and feed and water deprivation during transport and at livestock markets. The objectives of this study were to describe the diverse management of cull dairy cows in Canada and establish consensus on ways to achieve improvements. A 2-day expert consultation meeting was convened, involving farmers, veterinarians, regulators, and experts in animal transport, livestock auction, and slaughter. The 15 participants, recruited from across Canada, discussed regional management practices for cull cattle, related risk factors, animal welfare problems, and recommendations. An audio recording of the meeting was used to extract descriptive data on cull cattle management and identify points of agreement. Eight consensus points were reached: (1) to assemble information on travel times and delays from farm to slaughter; (2) to increase awareness among producers and herd veterinarians of potential travel distances and delays; (3) to promote pro-active culling; (4) to improve the ability of personnel to assess animal condition before loading; (5) to identify local options for slaughter of cull dairy cows; (6) to investigate different management options such as emergency slaughter and mobile slaughter; (7) to ensure that all farms and auctions have, or can access, personnel trained and equipped for euthanasia; and (8) to promote cooperation among enforcement agencies and wider adoption of beneficial regulatory options.
Asunto(s)
Bienestar del Animal , Bovinos/fisiología , Transportes , Animales , Canadá , Consenso , Industria Lechera , Agricultores , Granjas , Femenino , Políticas , Derivación y ConsultaRESUMEN
A bioactive glass series (0.42SiO2-0.10Na2O-0.08CaO-(0.40-X)ZnO-(X)Ga2O3) was incorporated into carboxymethyl cellulose (CMC)/dextran (Dex) hydrogels in three different amounts (0.05, 0.10, and 0.25m(2)), and the resulting composites were characterized using transmission electron microscopy (TEM), differential scanning calorimetry (DSC), and (13)C Cross Polarization Magic Angle Spinning Nuclear Magnetic Resonance (CP MAS-NMR). Composite extracts were also evaluated in vitro against MG-63 osteosarcoma cells. TEM confirmed glass distribution throughout the composites, although some particle agglomeration was observed. DSC revealed that glass composition and content did have small effects on both Tg and Tm. MAS-NMR revealed that both CMC and Dex were successfully functionalized, that cross-linking occurred, and that glass addition did slightly alter bonding environments. Cell viability analysis suggested that extracts of the glass and composites with the largest Ga-content significantly decreased MG-63 osteosarcoma viability after 30days. This study successfully characterized this composite series, and demonstrated their potential for anti-cancerous applications.
Asunto(s)
Antineoplásicos/química , Carboximetilcelulosa de Sodio/análogos & derivados , Dextranos/química , Galio/química , Vidrio/química , Hidrogeles/química , Antineoplásicos/farmacología , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacología , Neoplasias Óseas/tratamiento farmacológico , Carboximetilcelulosa de Sodio/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Dextranos/farmacología , Galio/farmacología , Humanos , Hidrogeles/farmacología , Osteosarcoma/tratamiento farmacológicoRESUMEN
In this work, an all-atom molecular dynamics simulation technique was employed to gain insight into the dynamic structure of the solvation shell formed around C60 and phenyl-C61-butyric acid methyl ester (PCBM) in nine aromatic solvents. A new method was developed to visualize and quantify the distribution of solvent molecule orientations in the solvation shell. A strong positive correlation was found between the regularity of solvent molecule orientations in the solvation shell and the experimentally obtained solubility limits for both C60 and PCBM. This correlation was extended to predict a solubility of 36 g/L for PCBM in 1,2,4-trimethylbenze. The relationship between solvation-shell structure and solubility provided detailed insight into solvate formation of C60 and solvation in relation to solvent molecular structure and properties. The determined dependence of the solvation-shell structure on the geometric shape of the solvent might allow for enhanced control of fullerene solution-phase behavior during processing by chemically tailoring the solvent molecular structure, potentially diminishing the need for costly and environmentally harmful halogenated solvents and/or additives.
RESUMEN
BARREL observed electron precipitation over wide range of energy and timescalesPrecipitating electron distribution is determined using spectroscopy for 19 January 2013 eventBARREL timing data has accuracy within sampling interval of 0.05 s.
RESUMEN
We demonstrate the hohlraum radiation temperature and symmetry required for ignition-scale inertial confinement fusion capsule implosions. Cryogenic gas-filled hohlraums with 2.2 mm-diameter capsules are heated with unprecedented laser energies of 1.2 MJ delivered by 192 ultraviolet laser beams on the National Ignition Facility. Laser backscatter measurements show that these hohlraums absorb 87% to 91% of the incident laser power resulting in peak radiation temperatures of T(RAD)=300 eV and a symmetric implosion to a 100 µm diameter hot core.
RESUMEN
Loss of progesterone secretion at the end of the estrous cycle is via uterine PGF(2alpha) secretion; however, uterine PGF(2alpha) is not decreased during early pregnancy in ewes to prevent luteolysis. Instead the embryo imparts resistance to PGF(2alpha)-induced luteolysis, which is via the 2-fold increase in prostaglandins E(1) and E(2) (PGE(1), PGE(2); PGE) in the endometrium during early pregnancy. Chronic intrauterine infusion of PGE(1) or PGE(2) prevents spontaneous or an estradiol-17beta, IUD, or PGF(2alpha)-induced luteolysis. Four PGE receptor subtypes (EP(1), EP(2), EP(3), and EP(4)) and an FP receptor specific for PGF(2alpha) have been identified. The objective of this experiment was to determine the effects of EP(1), EP(2), EP(3), or FP receptor agonists in vivo on luteal mRNA for LH receptors, occupied and unoccupied LH receptors, and circulating progesterone in ewes. Ewes received a single treatment of 17-phenyl-tri-Nor-PGE(2) (EP(1), EP(3)), butaprost (EP(2)), 19-(R)-OH-PGE(2) (EP(2)), sulprostone (EP(1), EP(3)), or PGF(2alpha) (FP) receptor agonists into the interstitial tissue of the ovarian vascular pedicle adjacent to the luteal-containing ovary. 17-Phenlyl-tri-Nor-PGE(2) had no effect (P> or =0.05) on any parameter analyzed. Butaprost and 19-(R)-OH-PGE(2) increased (P< or =0.05) mRNA for LH receptors, occupied and unoccupied LH receptors, and circulating progesterone. Both sulprostone and PGF(2alpha) decreased (P< or =0.05) mRNA for LH receptors, occupied and unoccupied LH receptors, and circulating progesterone. It is concluded that both EP(3) and FP receptors may be involved in luteolysis. In addition, EP(2) receptors may mediate prevention of luteolysis via regulation of luteal mRNA for LH receptors to prevent loss of occupied and unoccupied LH receptors and therefore to sustaining luteal function.
Asunto(s)
Cuerpo Lúteo/efectos de los fármacos , Cuerpo Lúteo/fisiología , Receptores de Prostaglandina E/agonistas , Receptores de Prostaglandina/agonistas , Ovinos , Animales , Cuerpo Lúteo/anatomía & histología , Cuerpo Lúteo/metabolismo , Ciclo Estral/efectos de los fármacos , Ciclo Estral/metabolismo , Femenino , Células Lúteas/efectos de los fármacos , Células Lúteas/metabolismo , Tamaño de los Órganos/efectos de los fármacos , Embarazo , Progesterona/sangre , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores de HL/genéticaRESUMEN
Loss of luteal progesterone secretion at the end of the ovine estrous cycle is via uterine PGF(2)alpha secretion. However, uterine PGF(2)alpha secretion is not decreased during early pregnancy in ewes. Instead, the embryo imparts a resistance to PGF(2)alpha. Prostaglandins E (PGE; PGE(1)+PGE(2)) are increased in endometrium and uterine venous blood during early pregnancy in ewes to prevent luteolysis. Chronic intrauterine infusion of PGE(1) or PGE(2) prevents spontaneous or IUD, estradiol-17beta, or PGF(2)alpha-induced premature luteolysis in nonbred ewes. The objective was to determine whether chronic intrauterine infusion of PGE(1) or PGE(2) affected mRNA for LH receptors, occupied and unoccupied receptors for LH in luteal and caruncular endometrium, and luteal function. Ewes received Vehicle, PGE(1), or PGE(2) every 4h from days 10 to 16 of the estrous cycle via a cathether installed in the uterine lumen ipsilateral to the luteal-containing ovary. Jugular venous blood was collected daily for analysis of progesterone and uterine venous blood was collected on day-16 for analysis of PGF(2)alpha and PGE. Corpora lutea and caruncular endometrium were collected from day-10 preluteolytic control ewes and day-16 ewes treated with Vehicle, PGE(1) or PGE(2) for analysis of the mRNA for LH receptors and occupied and unoccupied receptors for LH. Luteal weights on day-16 in ewes treated with PGE(1) or PGE(2) and day-10 control ewes were similar (P>or=0.05), but were greater (PAsunto(s)
Alprostadil/farmacología
, Cuerpo Lúteo/efectos de los fármacos
, Endometrio/efectos de los fármacos
, Hormona Luteinizante/metabolismo
, Luteólisis/efectos de los fármacos
, Receptores de HL/genética
, Receptores de HL/metabolismo
, Alprostadil/administración & dosificación
, Animales
, Cuerpo Lúteo/metabolismo
, Cuerpo Lúteo/fisiología
, Dinoprostona/administración & dosificación
, Dinoprostona/farmacología
, Endometrio/metabolismo
, Endometrio/fisiología
, Ciclo Estral/efectos de los fármacos
, Ciclo Estral/genética
, Ciclo Estral/metabolismo
, Femenino
, Regulación de la Expresión Génica/efectos de los fármacos
, Luteólisis/genética
, Luteólisis/metabolismo
, ARN Mensajero/genética
, ARN Mensajero/metabolismo
, Ovinos
, Factores de Tiempo
RESUMEN
Endothelin-1 (ET-1) has been reported to mediate prostaglandin (PG) F(2)alpha (PGF(2)alpha)-induced luteolysis. Prostaglandins E (PGE; PGE(1)+PGE(2)) are associated with implantation, maternal recognition of pregnancy, and are antiluteolytic and luteotropic in vitro and in vivo. ET-1 increased PGE secretion by bovine luteal tissue in vitro from cows where estrus was not synchronized or when estrus was synchronized with lutalyse and did not affect luteal PGF(2)alpha or progesterone secretion, which does not support the concept that ET-1 is luteolytic or mediates PGF(2)alpha luteolysis. Therefore, the objective of this experiment was to determine whether ET-1 infused every 6h from 2400 h on day 10-1800 h on day 18 of the ovine estrous cycle either into the interstitial tissue of the ovarian vascular pedicle (IP) or intrauterine (IU) adjacent to the luteal-containing ovary was luteolytic in ewes. Treatments were: Vehicle-IP; Vehicle-IU; ET-1-IP; or ET-1-IU. Weights of corpora lutea differed (P< or = 0.05) among treatment groups. Weights of corpora lutea at 1800 h on day 18 were: VEH-IP-247+/-38 mg; VEH-IU-195+/-31 mg; ET-1-IP-626+/-74 mg; and ET-1-IU-542+/-69 mg. Luteal weights on day 18 in ET-1-IP or ET-1-IU-treated ewes did not differ (P> or =0.05), but were heavier (P< or =0.05) than in the Vehicle-IP or Vehicle-IU treatment groups which did not differ (P> or =0.05). Profiles of progesterone in jugular venous plasma of both control groups treated with Vehicle-IP or Vehicle-IU were lower (P< or =0.05) than in ewes treated with ET-1-IP or ET-1-IU, which did not differ (P> or =0.05) between ET-1-IP or ET-1-IU treatment groups. Treatment with ET-1-IP or ET-1-IU increased (P< or =0.05) the PGE:PGF(2)alpha ratio when compared to the Vehicle-IP or Vehicle-IU treatment groups, which did not differ (P> or =0.05) between each other. In summary, ET-1 prevented the decrease in luteal weights and the decline in progesterone, but increased the PGE:PGF(2)alpha ratio when compared to controls. Therefore, it is concluded that ET-1 is not luteolytic in ewes, but instead may be luteotropic or antiluteolytic by altering uterine secretion of the PGE:PGF(2)alpha ratio, since PGE(1) or PGE(2) are luteotropic in vitro and in vivo, PGE(1) or PGE(2) prevent PGF(2)alpha-induced luteolysis in vitro and in vivo, and PGE(1) and PGE(2) increase two-fold in ewe endometrium to prevent luteolysis during early pregnancy.
Asunto(s)
Cuerpo Lúteo/fisiología , Endotelina-1/fisiología , Luteólisis/fisiología , Ovinos/fisiología , Animales , Dinoprost/sangre , Femenino , Tamaño de los Órganos , Embarazo , Progesterona/sangre , Prostaglandinas E/sangre , Ovinos/sangreRESUMEN
Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children. Although a pediatric dosage is proposed by the manufacturer, no data are currently available on the pharmacokinetics of amprenavir in neonates and infants. Amprenavir being primarily eliminated after oxidative biotransformation, we explored its in vitro metabolism by cytochrome P450 (P450)-dependent monooxygenases. In our conditions, five metabolites were formed in vitro and subsequently analyzed by liquid chromatography-mass spectrometry; P450-dependent oxidations occurred either on the tetrahydrofuran ring (M3 and M4), the aniline ring (M5), and the aliphatic chain (M2) or resulted from the N-dealkylation and loss of the tetrahydrofuran ring (M1). The two major metabolites, respectively M3 and M2 were formed by human liver microsomes with K(m) between 10 and 70 microM. CYP3A4 and to a lesser extent CYP3A5 were major contributors for the formation of M2, M3, and M5 metabolites, whereas CYP3A7 had no or little activity. This assumption was confirmed by inhibition with ketoconazole and ritonavir (two potent inhibitors of CYP3A) whereas sulfaphenazole (2C9 inhibitor) and quinidine (2D6 inhibitor) were inefficient. The metabolism of amprenavir was negligible in microsomes from either fetuses or neonates and steadily increased after the first weeks of life in relation with the maturation of CYP3A4/5. In conclusion, results demonstrated that the capacity of the human liver to oxidize amprenavir is low during the first weeks after birth and that dosage could be substantially reduced during the early neonatal period.
Asunto(s)
Sistema Enzimático del Citocromo P-450/fisiología , Feto/metabolismo , Hígado/embriología , Hígado/enzimología , Sulfonamidas/metabolismo , Adulto , Carbamatos , Células Cultivadas , Citocromo P-450 CYP3A , Sistema Enzimático del Citocromo P-450/biosíntesis , Sistema Enzimático del Citocromo P-450/metabolismo , Feto/enzimología , Furanos , Humanos , Lactante , Recién Nacido , Hígado/crecimiento & desarrollo , Hígado/metabolismo , Microsomas Hepáticos/enzimología , Microsomas Hepáticos/metabolismo , Oxidación-Reducción , Procesamiento Proteico-Postraduccional/fisiología , Sulfonamidas/análisis , Sulfonamidas/químicaRESUMEN
1. The urinary metabolites of the anti-convulsant compound 4-amino-1-(2,6-difluorobenzyl)-1H-1,2,3-triazolo[4,5-c]-pyridine hydrochloride (GI265080) obtained following a single oral dose to man have been detected and quantified relative to each other using 19F-NMR spectroscopy. 2. The human urinary metabolites of GI265080 were isolated using semipreparative HPLC and unequivocally characterized using 1H-NMR spectroscopy, two-dimensional heteronuclear NMR spectroscopy and mass spectrometry. The assignments of the N-(5)-oxide and the N-(5)-O-glucuronide metabolites of GI265080 were further confirmed by independent synthesis. The urinary metabolites obtained following single oral doses to dog and rat have also been isolated and characterized. 3. The human urinary metabolites of GI265080 comprise the N-(5)-oxide, the quaternary N+-(5)-glucuronide, the 7-hydroxy glucuronide and a glucuronide conjugate of the N-(5)-oxide. The N-(5)-O-glucuronide conjugate is a novel species in human metabolism and is a significant route of elimination of GI265080 in man. 4. The urinary metabolites of the potential anti-convulsant GW273293 (6-amino-3-(2,3,5-trichlorophenyl)pyrazin-2-ylamine) obtained following a single oral dose to man have also been isolated and characterized. The formation of a novel N-O-glucuronide was also observed and was shown to constitute a significant route of elimination of GW273293 in man.
Asunto(s)
Anticonvulsivantes/química , Anticonvulsivantes/metabolismo , Fluorobencenos/química , Fluorobencenos/metabolismo , Pirazinas/química , Pirazinas/metabolismo , Animales , Anticonvulsivantes/orina , Perros , Femenino , Flúor , Fluorobencenos/orina , Glucurónidos/química , Glucurónidos/metabolismo , Glucurónidos/orina , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Espectrometría de Masas , Estructura Molecular , Pirazinas/orina , Ratas , Ratas Sprague-DawleyRESUMEN
Activation of the epidermal growth receptor (ErbB1) occurs within minutes of a radiation exposure. Immediate downstream consequences of this activation are currently indistinguishable from those obtained with growth factors (GF), e.g. stimulation of the pro-proliferative mitogen-activated protein kinase (MAPK). To identify potential differences, the effects of GFs and radiation on other members of the ErbB family have been compared in mammary carcinoma cell lines differing in their ErbB expression profiles. Treatment of cells with EGF (ErbB1-specific) or heregulin (ErbB4-specific) resulted in a hierarchic transactivations of ErbB2 and ErbB3 dependent on GF binding specificity. In contrast, radiation indiscriminately activated all ErbB species with the activation profile reflecting that cell's ErbB expression profile. Downstream consequences of these ErbB interactions were examined with MAPK after specifically inhibiting ErbB1 (or 4) with tyrphostin AG1478 or ErbB2 with tyrphostin AG825. MAPK activation by GFs or radiation was completely inhibited by AG1478 indicating total dependance on ErbB1 (or 4) depending on which ErbB is expressed. Inhibiting ErbB2 caused an enhanced MAPK response simulating an amplified ErbB1 (or 4) response. Thus ErbB2 is a modulator of ErbB1 (or 4) function leading to different MAPK response profiles to GF or radiation exposure.
Asunto(s)
Neoplasias de la Mama/radioterapia , Carcinoma/radioterapia , Genes erbB , Radiación Ionizante , Proteínas Tirosina Quinasas Receptoras/efectos de la radiación , Comunicación Autocrina , Benzotiazoles , Factor de Crecimiento Epidérmico/farmacología , Receptores ErbB/metabolismo , Receptores ErbB/efectos de la radiación , Femenino , Sustancias de Crecimiento/farmacología , Humanos , Neurregulina-1/farmacología , Quinazolinas , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptor ErbB-2/metabolismo , Receptor ErbB-2/efectos de la radiación , Receptor ErbB-3/metabolismo , Receptor ErbB-3/efectos de la radiación , Receptor ErbB-4 , Transducción de Señal , Células Tumorales Cultivadas , Tirfostinos/farmacologíaRESUMEN
Despite much information as to the structure and function of the general transcription factors, little is known about the regulation of their expression. Transcription of the Saccharomyces cerevisiae SUA7 (TFIIB) gene results in the formation of two discrete transcripts. It was originally reported that the two transcripts were derived from two promoters separated by approximately 80 bp. We have found that the two transcripts are instead derived from a common promoter and differ at the 3'-end by approximately 115 bp. The longer of the two transcripts has an unusually long 3'-untranslated region. We have analyzed the levels of these transcripts under different cell growth conditions and find that the relative amounts of the two transcripts vary. Approximately equal amounts of each transcript are observed during exponential growth, but stresses and growth limiting conditions lead to a decrease in the relative amount of the larger transcript. These results suggest that the expression of the SUA7 gene may be controlled by regulation of 3'-end formation or mRNA stability. One of the general transcription factors, then, may be subject to regulation by a general response of the mRNA processing machinery.
Asunto(s)
Regiones no Traducidas 3'/genética , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/genética , Factor de Transcripción TFIIB , Factores de Transcripción/genética , Secuencia de Bases , Northern Blotting , ADN Complementario/química , ADN Complementario/genética , Regulación Fúngica de la Expresión Génica , Datos de Secuencia Molecular , ARN de Hongos/genética , ARN de Hongos/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Saccharomyces cerevisiae/crecimiento & desarrollo , Análisis de Secuencia de ADN , Transcripción GenéticaRESUMEN
QSARs based upon the logarithm of the octanol-water partition coefficient, log P, and energy of the lowest unoccupied molecular orbital, ELUMO were developed to model the toxicity of aliphatic compounds to the marine bacterium Vibrio fischeri. Statistically robust, hydrophobic-dependent QSARs were found for chloroalcohols and haloacetonitriles. Modelling of the toxicity of the haloesters and the diones required the use of terms to describe both hydrophobicity and electrophilicity. The differences in intercepts, slopes, and fit of these models suggest different electrophilic mechanisms occur between classes, as well as within the diones and haloesters. In order to model globally the toxicity of aliphatic compounds to V. fischeri, all the data determined in this study were combined with those determined previously for alkanones, alkanals, and alkenals. A highly predictive two-parameter QSAR [pT15 = 0.760(log P) - 0.625(ELUMO) - 0.466; n = 63, s = 0.462, r2 = 0.846, F = 171, Pr > F = 0.0001] was developed for the combined data that models across classes and is independent of mechanisms of action. The toxicity of these compounds to V. fischeri compares well to the toxicity (50% population growth inhibition) to the ciliate Tetrahymena pyriformis (r2 = 0.850).
Asunto(s)
Toxinas Bacterianas/toxicidad , Relación Estructura-Actividad Cuantitativa , Vibrio/patogenicidad , Toxinas Bacterianas/farmacocinética , Fenómenos Químicos , Química Física , Ácidos Grasos/farmacocinética , Ácidos Grasos/toxicidad , Pruebas de Toxicidad , Vibrio/químicaRESUMEN
This case report histologically examines the type of attachment that can occur after root coverage of a long-standing facial recession defect on a maxillary premolar with a subepithelial connective tissue graft. Histologic findings suggest that various types of tissue attachment, including periodontal regeneration, may occur over a recession defect after placement of a subepithelial connective tissue graft. In the present case, it was noteworthy that after 1 year the greatest area of exposed root surface was covered by a connective tissue attachment (adhesion), which had remained intact during orthodontic movement and distal drifting of the tooth.
Asunto(s)
Encía/trasplante , Recesión Gingival/cirugía , Gingivoplastia , Biopsia , Regeneración Ósea , Tejido Conectivo/patología , Tejido Conectivo/trasplante , Cemento Dental/anatomía & histología , Inserción Epitelial/anatomía & histología , Humanos , Masculino , Persona de Mediana Edad , Ligamento Periodontal/anatomía & histología , Regeneración , Adherencias Tisulares/patología , Técnicas de Movimiento Dental , Resultado del TratamientoRESUMEN
There is substantial clinical and histological evidence that support the concept that extraoral and intraoral autogenous bone grafts and demineralized freeze-dried bone allografts are effective regenerative materials in the treatment of intrabony defects. Moreover, long-term evaluations currently available suggest that the regenerative gains achieved remain clinically stable. Synthetic grafts may result in improved probing depths and clinical attachment levels but have yet to demonstrate the ability to initiate or enhance the formation of a new attachment apparatus.
Asunto(s)
Pérdida de Hueso Alveolar/cirugía , Alveoloplastia/métodos , Trasplante Óseo/métodos , Regeneración Ósea , Sustitutos de Huesos , HumanosRESUMEN
In today's environment, home care professionals are often overwhelmed with documentation requirements. Licensure and certification surveyors, Office of Inspector General staff, third-party payors, fraud and abuse inspectors, courtroom attorneys, and others seem to scrutinize home care documentation constantly. In short, home care documentation is always "on trial." These tips can help agencies protect themselves in this environment.
Asunto(s)
Agencias de Atención a Domicilio/organización & administración , Responsabilidad Legal , Registros Médicos/normas , Gestión de Riesgos/legislación & jurisprudencia , Confidencialidad , Continuidad de la Atención al Paciente , Documentación , Fraude/legislación & jurisprudencia , Agencias de Atención a Domicilio/legislación & jurisprudencia , Mala Praxis/legislación & jurisprudencia , Registros Médicos/legislación & jurisprudencia , Planificación de Atención al Paciente , Estados UnidosRESUMEN
Exposure of A431 squamous and MDA-MB-231 mammary carcinoma cells to ionizing radiation has been associated with short transient increases in epidermal growth factor receptor (EGFR) tyrosine phosphorylation and activation of the mitogen-activated protein kinase (MAPK) and c-Jun NH(2)-terminal kinase (JNK) pathways. Irradiation (2 Gy) of A431 and MDA-MB-231 cells caused immediate primary activations (0-10 min) of the EGFR and the MAPK and JNK pathways, which were surprisingly followed by later prolonged secondary activations (90-240 min). Primary and secondary activation of the EGFR was abolished by molecular inhibition of EGFR function. The primary and secondary activation of the MAPK pathway was abolished by molecular inhibition of either EGFR or Ras function. In contrast, molecular inhibition of EGFR function abolished the secondary but not the primary activation of the JNK pathway. Inhibition of tumor necrosis factor alpha receptor function by use of neutralizing monoclonal antibodies blunted primary activation of the JNK pathway. Addition of a neutralizing monoclonal antibody versus transforming growth factor alpha (TGFalpha) had no effect on the primary activation of either the EGFR or the MAPK and JNK pathways after irradiation but abolished the secondary activation of EGFR, MAPK, and JNK. Irradiation of cells increased pro-TGFalpha cleavage 120-180 min after exposure. In agreement with radiation-induced release of a soluble factor, activation of the EGFR and the MAPK and JNK pathways could be induced in nonirradiated cells by the transfer of media from irradiated cells 120 min after irradiation. The ability of the transferred media to cause MAPK and JNK activation was blocked when media were incubated with a neutralizing antibody to TGFalpha. Thus radiation causes primary and secondary activation of the EGFR and the MAPK and JNK pathways in autocrine-regulated carcinoma cells. Secondary activation of the EGFR and the MAPK and JNK pathways is dependent on radiation-induced cleavage and autocrine action of TGFalpha. Neutralization of TGFalpha function by an anti-TGFalpha antibody or inhibition of MAPK function by MEK1/2 inhibitors (PD98059 and U0126) radiosensitized A431 and MDA-MB-231 cells after irradiation in apoptosis, 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), and clonogenic assays. These data demonstrate that disruption of the TGFalpha-EGFR-MAPK signaling module represents a strategy to decrease carcinoma cell growth and survival after irradiation.
Asunto(s)
Neoplasias de la Mama/radioterapia , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Carcinoma/radioterapia , Receptores ErbB/metabolismo , Proteínas Quinasas JNK Activadas por Mitógenos , Quinasas de Proteína Quinasa Activadas por Mitógenos , Factor de Crecimiento Transformador alfa/metabolismo , Anticuerpos/farmacología , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Butadienos/farmacología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/antagonistas & inhibidores , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/radioterapia , Muerte Celular/efectos de la radiación , División Celular/efectos de la radiación , ADN sin Sentido/genética , Relación Dosis-Respuesta en la Radiación , Activación Enzimática/efectos de la radiación , Inhibidores Enzimáticos/farmacología , Receptores ErbB/genética , Humanos , MAP Quinasa Quinasa 4 , Nitrilos/farmacología , Fosforilación/efectos de la radiación , Proteínas Quinasas/metabolismo , Proteínas Quinasas/efectos de la radiación , Receptores del Factor de Necrosis Tumoral/metabolismo , Receptores del Factor de Necrosis Tumoral/efectos de la radiación , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Factor de Crecimiento Transformador alfa/inmunología , Factor de Crecimiento Transformador alfa/efectos de la radiación , Células Tumorales Cultivadas , Tirosina/metabolismoRESUMEN
Formalin-fixed, paraffin-embedded thyroid glands from 18 cats diagnosed with hyperthyroidism were evaluated immunohistochemically for overexpression of the products of oncogenes c-ras and bcl2 and the tumor suppressor gene p53. Fourteen thyroid glands from euthyroid cats without histologically detectable thyroid lesions were examined similarly as controls. Results from these investigations showed that all cases of nodular follicular hyperplasia/adenomas stained positively for overexpression of c-Ras protein using a mouse monoclonal anti-human pan-Ras antibody. The most intensely positively staining regions were in luminal cells surrounding abortive follicles. Subjacent thyroid and parathyroid glands from euthyroid cats did not stain immunohistochemically for pan-Ras. There was no detectable staining for either Bc12 or p53 in any of the cats. These results indicated that overexpression of c-ras was highly associated with areas of nodular follicular hyperplasia/adenomas of feline thyroid glands, and mutations in this oncogene may play a role in the etiopathogenesis of hyperthyroidism in cats.
Asunto(s)
Adenoma/veterinaria , Enfermedades de los Gatos/genética , Genes ras/genética , Hipertiroidismo/veterinaria , Glándula Tiroides/patología , Neoplasias de la Tiroides/veterinaria , Adenoma/genética , Adenoma/metabolismo , Animales , Anticuerpos Monoclonales , Enfermedades de los Gatos/metabolismo , Gatos , Femenino , Regulación Neoplásica de la Expresión Génica , Genes bcl-2/genética , Genes p53/genética , Hiperplasia/genética , Hiperplasia/veterinaria , Hipertiroidismo/genética , Hipertiroidismo/metabolismo , Inmunohistoquímica , Masculino , Proteínas Proto-Oncogénicas p21(ras)/genética , Proteínas Proto-Oncogénicas p21(ras)/metabolismo , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/metabolismoRESUMEN
Ionizing radiation activates the epidermal growth factor receptor (EGFR) and downstream signaling involving the cytoprotective mitogen-activated protein kinase (MAPK) pathway. In our effort to investigate the role of EGFR in cellular responses to radiation, we generated mammary carcinoma cell clones, MCF-TR5-EGFR-CD533 and MDA-TR15-EGFR-CD533, that inducibly express EGFR-CD533, a truncated EGFR mutant lacking mitogenic and transformation activity. EGFR-CD533 expression inhibits radiation- and EGF-induced EGFR autophosphorylation and MAPK activation and, therefore, functions as a dominant-negative mutant without blocking the expression of EGFR or erbB-2, another member of the erbB receptor Tyr kinase family. Expression of EGFR-CD533 only minimally inhibited cell growth and did not alter radiosensitivity to single radiation exposures. However, repeated 2 Gy radiation exposures of cells, under conditions of EGFR-CD533 expression, essentially abolished their ability for subsequent cell growth. These results identify the inhibition of EGFR function through genetic manipulation as a potential therapeutic maneuver. The concept of such an intervention would be the radiosensitization of cells by counteracting a radiation-induced cytoprotective proliferation response.
Asunto(s)
Receptores ErbB/biosíntesis , Tolerancia a Radiación , Neoplasias de la Mama , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , División Celular/efectos de los fármacos , División Celular/efectos de la radiación , Relación Dosis-Respuesta a Droga , Doxiciclina/farmacología , Receptores ErbB/genética , Femenino , Eliminación de Gen , Humanos , Cinética , ARN Mensajero/biosíntesis , Células Tumorales CultivadasRESUMEN
The purpose of this study was to determine the feasibility of regenerating bone in patients with advanced horizontal bone loss. Demineralized freeze-dried bone allografts (DFDBA) in particle, strut, and laminar forms were used in combination with guided tissue regeneration. The cortical struts and strips were processed from long bones and were supplied in different widths and lengths. The strips were prepared in various thicknesses ranging from 100 to 500 microns; the struts ranged from 1 to 3 mm thick. These 2 materials provided structural support for the retention of DFDBA particles supracrestally, and they supported the gingival flap as a space maintainer, preventing the collapse of the tissue onto the roots and existing bone. The results indicated successful supracrestal regeneration of horizontal defects when combining existing techniques and materials. The mean attachment gain for the 7 patients studied ranged from 2.6 to 3.0 mm.